Firebrick Pharma (ASX: FRE)

Firebrick Pharma (ASX: FRE) is making waves with its Nasodine Nasal Spray disinfectant, having recently executed an amended licence and distribution agreement to bring the product to the Philippines.  The amended agreement with S.V. More Pharma Corporation (SV More) allows for the local manufacture of Nasodine, shifting from its previous importation from Australia. This strategic

Pharmaceutical company Firebrick Pharma (ASX: FRE)’s Nasodine Nasal Spray has been launched in the United States and can now be purchased from the Company’s US website with online promotions will commencing this week across the US.  In the US, Nasodine will be promoted for ‘nasal hygiene’ without any therapeutic claims. Based on legal advice obtained

Can you spray away the common cold? Pharma company Firebrick Pharma (ASX: FRE) says yes. After completing two clinical trials, the Company has entered Phase 3 trials for its Nasodine Nasal Spray, which has enrolled 500 patients to trial the product.  The primary objective of the study is to assess the effectiveness of Nasodine compared

Biopharmaceutical company Starpharma (ASX: SPL) has received regulatory approval for its antiviral nasal spray product, VIRALEZE, in Malaysia. This milestone achievement grants Starpharma and its commercial partners the opportunity to market and sell the innovative product in Malaysia, a country with a population exceeding 33 million.  VIRALEZE has garnered significant recognition in Asia following successful

Offering some relief for people suffering from prostate cancer, Starpharma (ASX: SPL) might be on the verge of a breakthrough as it announced that its drug DEP® cabazitaxel has shown promising anti-tumour activity data at the European Society of Medical Oncology (ESMO) Congress in Paris, France.  The new data from its phase 2 trial reveals

We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available?  The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes.  Biopharmaceutical company Starpharma (ASX: SPL)